Abstract Submission Guidelines
*Extended* Abstract Deadline: July 15, 2020 @ 11:59PM, Eastern Daylight Time (EDT)
All accepted abstracts will be published on SIU Academy in ePoster format. No abstract book will be published for the virtual congress.
To ensure your abstract is eligible for submission, please take a few moments to review the guidelines and sample abstract below:
1. Submission Categories and Educational Objectives
To be considered for Best Abstract, please select the Standard ePoster option and submit 3 PowerPoint slides with a 2-minute audio in the submission form. Instructions on how to do so can be found here.
The 2020 Congress Learning Objectives are as follows:
After this educational event, attendees should be able to:
- Determine diagnosis and management of basic and complicated urological infections
- Describe the role of eHealth, new diagnostic methods and delivery of urological education and care in the developing world
- Summarize recent advances in molecular markers for urological diseases
- Report the application of therapeutic modalities and management of complex stone disease
- Discuss multimodal approach to treatment of urological cancers
- List recent advances in minimally invasive surgery
- Describe the current management of lower urinary tract symptoms
- Identify methods of dissemination of knowledge and care to underserved areas
2. Rules for Authors
Prior Publication of Material
The SIU Congress is a forum for the presentation of novel research findings. The work covered by the abstract must not have been published (manuscript or abstract) before October 10, 2020. If the work has been presented at another meeting, the author must disclose when and where it was presented (during submission process), so that the Abstract Review Committee can make its decision based on all available details.
Objectivity
The SIU is committed to offering participants an open forum for scientific discussion, wherein all scientists and clinicians are invited to contribute actively. To preserve this valuable environment, the SIU urges all presenters to avoid statements, symbols or other displays that are subjective and unscientific in nature.
Registration
Abstract status notifications will be sent to all submitters in August. All abstract authors are asked to register for the virtual event via SIU 2020 SIU@U platform. Registration is free, but required. More information is available here: https://www.siu-urology.org/congress-2020/siuu-reg.
Each abstract will be blinded and scored by up to three reviewers. Abstracts will be accepted on the basis of scientific merit.
Abstract Revisions
Abstracts may not be revised or resubmitted after the deadline of July 15, 2020.
Abstract Withdrawal
Please submit abstract withdrawal requests in writing via email to scientific.programme@siu-urology.org by October 1, 2020.
Change of Presenting Author
Please submit requests in writing via email to scientific.programme@siu-urology.org by October 1, 2020. After this date, changes will no longer appear online.
Publication and Copyright
3. Preparation of Abstracts
Language
Abstracts must be written and presented in English. Careful typing and proofreading is essential. If accepted, the abstract will be published as submitted. Errors, misspellings, incorrect hyphenation, and deviations from the use of correct English will be glaringly apparent in the published abstract. Once the abstract is submitted, changes, corrections or rewording will not be possible. Presenters are requested to devote the necessary attention to language in order to avoid deviations from the use of good English. The Scientific Committee reserves the right to reject abstracts which are presented in poor English or to request an immediate revision.
Word Count
Abstracts should not exceed 350 words. Deduct 50 words for each table or graph included (to a maximum of 1 page on US Letter, 8.5 x 11 inch paper.)
Images, Tables and Graphs
Images are not permitted, as they do not reproduce well. Brief and clear tables or graphs are accepted (maximum of 1 page on US Letter, 8.5 x 11 inch paper).
Topic Area
To ensure that your abstract receives proper scientific consideration, be sure to submit to the appropriate topic category as indicated on the web submission page.
Title of Abstract
Your abstract must have a short, specific title (no abbreviations) that indicates the nature of the investigation. Please use title case.
Sections
Abstracts MUST include the following four distinct sections:
- Introduction and Objectives
- Materials and Methods
- Results
- Conclusion
Drug Names
Use generic drug names.
Abbreviations
Standard abbreviations may be used without definition. Nonstandard abbreviations should be kept to a minimum and placed in parentheses after the first use of the word or phrase.
Acknowledgments
Do not include references, credits or grant support.
Author Names and Affiliations
List of authors: Do NOT include the authors list directly with your abstract. Only submit this information on the online authors form. There is only one presenting author permitted per submission. All authors must complete, sign and submit a Conflict of Interest disclosure form.
Spelling: If an author's name appears on more than one abstract, it must be identical on each abstract in order to ensure proper indexing.
Human Experimentation
Any human experimentation conducted as part of the submitted abstract(s) must follow the protocol approved by the institutional or local committee on ethics in human investigation; or, if no such committee exists, the investigation should have been conducted in accordance with the principles of the World Medical Association’s Helsinki Declaration. The Scientific Committee may inquire further into ethical aspects when evaluating the abstract(s).
Abstract Data
Abstracts that describe single clinical cases, or investigations of compounds that involve inadequate numbers of study subjects, or abstracts that lack quantitative data will not be accepted. Authors should not "split" data to create several abstracts from one. If splitting is judged to have occurred, priority scores of related abstracts will be reduced.
Abstracts containing identical or nearly identical data submitted from the same institution (and/or individuals) describing the same study population will be disqualified.
Statements such as "results will be discussed" will automatically disqualify the abstract. Reviewers require specific data on which to base their evaluation.
Bear in mind that your abstract will be rated according to the following criteria:
• Is the design of the study valid?
• Are the methods appropriate?
• What is the significance of the results?
• Is the event described in the case report significant?
3-4 Educational Objectives must be submitted for each abstract.
For more information, consult: Writing Clear Learning Objectives.
Complications in Laparoscopic Transperitoneal Partial Nephrectomy
Introduction and Objectives: We review the complications of laparoscopic partial nephrectomy in a single surgeon series.
Materials and Methods: Between July 1999 and April 2006, a total of 125 patients underwent laparoscopic transperitoneal partial nephrectomy. Mean patient age was 58 years (range 33 to 87) and male to female ratio was 2:1. In 43 patients (34%) the procedure was hand-assisted. A database was kept prospectively for all patients.
Results: Mean operative time was 104 minutes (range 35 to 180) and average surgical bleeding was 258 ml (range 0 to 2000). For procedures with warm ischemia, mean arterial clamping time was 26 minutes (range 15 to 60). Mean tumor size was 2.7 cm (range 1 to 7). A total of 14 patients (11.2%) had one or more complications which were intraoperative 6 (4.8%) and postoperative 8 (6.4%) with two delayed complications. Intraoperative hemorrhage occurred in 6 cases (4.8%), and postoperatively in another 6 (4.8%). Intraoperative hemorrhage was managed in 2 cases with laparoscopic radical nephrectomy and in 4 cases with intracorporeal suture. Postoperative hemorrhage required reoperation in 4 patients: two open radical nephrectomies, one laparoscopic radical nephrectomy and one laparoscopic re-suture of the kidney. The remaining two patients were managed with endovascular (percutaneous) embolization. Urine leakage occurred in one case (0.8%) and was managed conservatively with a double-J stent. A digestive hemorrhage and a pulmonary embolism were presented by two patients (1.6%). Transfusion rate was 10.4%. No case required conversion to open surgery. Mean hospital stay was 3.6 days (range 1 to 12).
Conclusion: Laparoscopic transperitoneal partial nephrectomy is technically demanding with a high potential for complications. The most frequent complication is either intra- or post-operative hemorrhage. For delayed bleeding, endovascular techniques are safe and effective and thus our first choice in the stable patient.
4. Video Submissions
Submission
If you wish to submit a video, please use the following link to upload your file: http://www.siu-urology.org/vimeoapi/
Please note that videos MUST be uploaded prior to the submission deadline in order to be considered for review, and also note that a video submission MUST include an abstract.
Format
All videos must be in the final format and include the exact title, presenting author and production date in the submission title. The video itself should be blinded for review. Maximum duration of video: 7 minutes. Submitters may wish to include commentary. All audio and written commentary must be in English.
For any questions pertaining to your abstract submission, please contact: scientific.programme@siu-urology.org.